Results: FES-patients scored lower than the control group across all cognitive domains at baseline. Over six years, the cognitive trajectories of visual learning seem to remain stable for both groups, while FES-patients showed slight improvements in attention (β = 1.34, SE = .18, p < .001), verbal learning (β = .65, SE = .29, p < .031), processing speed (β = .69, SE = .35, p < .051), reasoning/ problem solving (β = 1.68, SE = .27 p < .001), working memory (β = .89, SE = .27, p < .002) and social cognition (β = .93, SE = .30, p < .003). Most of these cognitive trajectories start to improve within the first year of illness and continues throughout the six year period. The improvement in processing speed (β = .18, SE = .48, p > .05), verbal learning (β = .56, SE = .59, p > .05) and social cognition (β = .82, SE = .59, p > .05) seem to be larger for FES-patients compared to controls, but these differences were not significant. The patient group's improvement in reasoning/ problem solving (β = 1.31, SE = .51, p < .05) was significantly larger that the control group, but they showed smaller improvement in working memory (β = -1.03, SE = .51, p < .05). Discussion: Our results show that improvements are already discernable after 6 months following illness outbreak. There are different trajectories for different cognitive domains. Moreover, two cognitive domain trajectories were significantly different between control group and FES-patients. This points to the importance of assessing cognitive development over many years with multiple assessments when exploring cognitive impairments in schizophrenia. From a clinical perspective, this may speak in favor of a targeted rehabilitation of different cognitive domains. Background: In recent years, the effect of cannabis use on cognitive functions in patients with psychosis has been widely studied, but results are somewhat contradictory. On the other hand, it has also been studied the relevance of the age of onset of consume, suggesting that the early age of onset of consumption may be related to a greater cognitive impairment. Methods: 349 patients with a first episode of non-affective psychosis were studied. Patients were classified in cannabis users and non-users. Users were divided according to their age at the beginning of use of cannabis in: earlyonset (age<16) and late-onset (≥16 years-old). Differences between groups at baseline were studied on sociodemographic, clinical and cognitive variables. The groups were longitudinally (3-year) compared on cognitive variables. Results: Out of the 349 patients included in this study, 38.7% (N=135) were cannabis users, of them 39.3% (N=53) started consuming before 16 years of age and 60.7% (N=82) did so at age 16 of after. No differences were found between early-onset and late-onset groups on cognitive domains. However, cannabis users (early and late) showed significantly worse performance in processing speed than non-users. Longitudinal analises revealed that the groups of early-onset, late-onset and non-users of cannabis, had different evolution in processing speed domain and in the global cognitive functioning. Discussion: The main findings of this study were that, although there were differences between patients who used cannabis and those who did not, minimal differences aroused between the early-onset and late-onset cannabis users. With respect to longitudinal analyses, we must be careful with their interpretation, since although a priori we found a significant group by time interaction (early-onset, late-onset, and non-users) in some domain, when the cannabis use at 3-year follow-up was considered, results did not show any significance, this reveals that cannabis users (early-onset and lateonset) and non-cannabis users did not differ in the degree of change in their
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Esther Setién-Suero* Background: In recent years, the effect of cannabis use on cognitive functions in patients with psychosis has been widely studied, but results are somewhat contradictory. On the other hand, it has also been studied the relevance of the age of onset of consume, suggesting that the early age of onset of consumption may be related to a greater cognitive impairment. Methods: 349 patients with a first episode of non-affective psychosis were studied. Patients were classified in cannabis users and non-users. Users were divided according to their age at the beginning of use of cannabis in: earlyonset (age<16) and late-onset (≥16 years-old). Differences between groups at baseline were studied on sociodemographic, clinical and cognitive variables. The groups were longitudinally (3-year) compared on cognitive variables. Results: Out of the 349 patients included in this study, 38.7% (N=135) were cannabis users, of them 39.3% (N=53) started consuming before 16 years of age and 60.7% (N=82) did so at age 16 of after. No differences were found between early-onset and late-onset groups on cognitive domains. However, cannabis users (early and late) showed significantly worse performance in processing speed than non-users. Longitudinal analises revealed that the groups of early-onset, late-onset and non-users of cannabis, had different evolution in processing speed domain and in the global cognitive functioning. Discussion: The main findings of this study were that, although there were differences between patients who used cannabis and those who did not, minimal differences aroused between the early-onset and late-onset cannabis users. With respect to longitudinal analyses, we must be careful with their interpretation, since although a priori we found a significant group by time interaction (early-onset, late-onset, and non-users) in some domain, when the cannabis use at 3-year follow-up was considered, results did not show any significance, this reveals that cannabis users (early-onset and lateonset) and non-cannabis users did not differ in the degree of change in their cognitive functions, regardless of whether or not the patients had maintained consumption during the first 3-year of disease progression. Results: CBQ total scores did not differed between patients with schizophrenia (45.3 ± 8.2) and high school students (44.2 ± 6.7). No significant differences between groups were found in any of the five cognitive biases. When exploring the relationship between cognitive biases and psychopathological symptoms in patients with schizophrenia, total CBQ scores were associated with CDSS scores (r= 0.65, p<0.001). In relation to particular cognitive biases, depressive symptoms were associated with all cognitive biases (I: r= 0.43, p= 0.017; C: r= 0.62, p<0.001; DT: r= 0.42, p= 0.020; JTC: r= 0.46, p= 0.012; ER: r= 0.57, p= 0.001), positive symptoms with ER (r= 0.43, p= 0.009) and general psychopathology symptoms of the PANSS with C (r= 0.34, p= 0.044), DT (r= 0.35, p= 0.041) and ER (r= 0.45, p= 0.007).
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In high school students, CBQ total scores were associated with positive (r= 0.43, p= 0.003) and depressive (r= 0.35, p= 0.020) symptoms. In relation to particular cognitive biases, depressive symptoms were associated with DT (r= 0.47, p= 0.001) whereas positive symptoms were associated with DT (r= 0.31, p= 0.036) and ER (r= 0.30, p= 0.047). Discussion: Although we did not find significant differences in the presence of cognitive biases when comparing two different samples, similar associations were found when exploring the relationship between cognitive biases and psychopathology symptoms. Our results are in accordance previous studies reporting the role of some cognitive biases on the risk of developing psychotic symptoms. On the other hand, a clear association between cognitive biases was found for depressive symptoms in both patients with schizophrenia and high school students. Our study highlights the importance of identifying and treating cognitive biases with appropriate therapies (e.g. metacognitive training) for improving the outcome of psychoses in both patients and people at risk for developing a psychotic disorder in the future. Background: Negative symptoms are core to schizophrenia. Understanding the complex way specific symptom profiles may affect cognition independent of a diagnosis of schizophrenia per se will allow for an improved understanding of the disorder, and specific subtypes as well as potential treatment targets therein. Methods: The neurocognitive profiles of 132 patients with schizophrenia/ schizoaffective disorder and 189 healthy controls were examined using the MATRICS Consensus Cognitive Battery. Patients were grouped as either having a negative symptom profile or no negative symptoms using the PANSS. Healthy controls were grouped as high or low schizotypy on the negative symptom analogue subscale from the O-LIFE. Results: There was a significant effect of negative symptom profile on the processing speed domain, the participants with negative symptoms performed significantly worse than those with no negative symptoms, after controlling for premorbid IQ, F(1,129)=4.30, p<0.05. The same relationship with speed of processing was found when investigating high vs low schizotypal aspects of negative symptoms in an equivalent analysis of healthy controls, with those scoring highly on negative symptoms performing significantly worse, after premorbid IQ was controlled for, F(1,186)=6.24, p<0.05. Discussion: The processing speed domain seems significantly impacted by negative symptom profile in both schizophrenia patients and healthy controls. The speed of processing deficits does not seem to be presenting a bottom up influence on higher order cognitive tasks, as no group differences were observed on reasoning and problem solving tasks. In conclusion, these findings indicate that the negative symptom cluster contributes to this specific cognitive impairment independently of the disorder.
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